Ongoing Efforts to Tailor Immunotherapy and Targeted Therapy for Melanoma

To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.

Step Status
Video/Document(s)
Posttest
Evaluation
Starts On: 7/1/2019: 12:00 AM
Ends On: 6/30/2020: 12:00 AM
Session Type: Internet Activity Enduring Material
Credits: 0.5
Description:

Faculty

Tanner M. Johanns, MD, PhD
Instructor
Department of Medicine, Oncology Division, Medical Oncology
Financial Relationships: Speaker has nothing to disclose

Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Melanoma Oncology in the Early Precision Medicine Era, March 9, 2019, which was supported in part by Bristol-Myers Squibb and Novartis Pharmaceuticals.

Planning Committee

George Ansstas, MD, Assistant Professor of Medicine, Division of Oncology
Financial Relationships:
- Consulting/Advisory Committees: Array BioPharma, Inc
- Speakers' Bureau/Honoraria: Bristol-Myers Squibb, Merck & Company, Novocure
- Research Support/Grants: Bristol-Myers Squibb, Kartos Therapeutics, Inc, Genentech, Novartis

Charles K. Kaufman, MD, PhD, Assistant Professor of Medicine, Division of Oncology
Financial Relationships: Speaker has nothing to disclose

Janelle E. Mann, PharmD, BCOP, Clinical Oncology Pharmacist, Division of Oncology
Financial Relationships: Speaker has nothing to disclose

James R. Wischmeier, MSN, APRN, FNP-C, OCN, Family Nurse Practitioner, Division of Oncology
Financial Relationships: Speaker has nothing to disclose

Objectives: The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
  • Describe the basis for recent improvement in outcomes for patients with melanoma brain metastases
  • Summarize the basis for preferred use of immunotherapy over targeted therapy for patients with melanoma brain metastases
  • Review the basis for preferred use of combination PD-1/CTLA-4 therapy over monotherapy in patients with melanoma brain metastases
Additional Information:
Target Audience: This course is designed for oncology specialists, primary care, and dermatologists, general surgeons, anesthesiologists, hospitalists, internists, family practice and emergency medicine physicians, as well as, pharmacists, physician assistants, nurse practitioners and nurses in these fields.

Publication Date: July 1, 2019
Expiration Date: June 30, 2020

Accreditation Information:
wustlcme
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Awarded for this Activity:
Credit Statement:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

References:
  • Cancer. 2018 Jan 15;124(2):297-305
  • https://doi.org/10.1016/j.ejca.2018.12.023
  • Adv Radiat Oncol. 2017 Aug 12;2(4):572-580.
  • Davies Lancet Oncol VOLUME 18, ISSUE 7 , P863-873, JULY 01, 2017
Disclosure Information: It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.

Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.

These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
Categories: Oncology, Surgery


Powered By AI 4.5